In the absence of a submission from the holder of the marketing authorisation, vildagliptin/metformin hydrochloride (Eucreas®) cannot be endorsed for use within NHS Wales for: treatment of type 2 diabetes mellitus in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea; or treatment of type 2 diabetes mellitus as triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.